{"id":"trandolapril-verapamil","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":{"chemblId":"CHEMBL1519","moleculeType":"Small molecule","molecularWeight":"430.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination drug pairs an ACE inhibitor (trandolapril) that prevents conversion of angiotensin I to angiotensin II with a non-dihydropyridine calcium channel blocker (verapamil) that reduces cardiac contractility and peripheral vascular resistance. Together, they provide complementary antihypertensive and cardioprotective effects, with verapamil also offering rate-control benefits in certain arrhythmias.","oneSentence":"Trandolapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while verapamil blocks calcium channels to slow heart rate and further lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:29.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT01127139","phase":"","title":"Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Abbott","startDate":"2010-04","conditions":"Essential Hypertension","enrollment":3828},{"nctId":"NCT00133692","phase":"PHASE4","title":"INVEST: INternational VErapamil SR Trandolapril STudy","status":"COMPLETED","sponsor":"University of Florida","startDate":"1997-09","conditions":"Hypertension, Coronary Artery Disease","enrollment":22000},{"nctId":"NCT01079195","phase":"","title":"Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-10","conditions":"Hypertension","enrollment":15436},{"nctId":"NCT00233532","phase":"PHASE4","title":"Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-03","conditions":"Hypertension","enrollment":2000},{"nctId":"NCT00234871","phase":"PHASE4","title":"Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-01","conditions":"Hypertension, Diabetes, Proteinuria","enrollment":357},{"nctId":"NCT00234858","phase":"PHASE4","title":"Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-03","conditions":"Hypertension, Metabolic Syndrome","enrollment":280},{"nctId":"NCT00235014","phase":"PHASE4","title":"A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)","status":"COMPLETED","sponsor":"Abbott","startDate":"1997-03","conditions":"Hypertension, Diabetes","enrollment":1204},{"nctId":"NCT00235001","phase":"PHASE4","title":"Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-06","conditions":"Hypertension","enrollment":120},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00679653","phase":"PHASE3","title":"Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-02","conditions":"Obesity, Hypertension","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-TARKA","Tarka","VeraTran"],"phase":"marketed","status":"active","brandName":"trandolapril/verapamil","genericName":"trandolapril/verapamil","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trandolapril/verapamil is an oral antihypertensive medication that combines a calcium channel blocker, verapamil, and an angiotensin-converting enzyme inhibitor, trandolapril. It is used to treat conditions such as hypertension, essential hypertension, and proteinuria, as well as other conditions including obesity and diabetes, as studied in clinical trials.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-10-22T00:00:00.000Z","mah":"ABBVIE","brand_name_local":"TARKA","application_number":"NDA020591"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}